Sanofi-Aventis Deutschland GmbH secures contract for Pharmaceutical products drug framework discount agreement in accordance with Section 130a Paragraph 8 and Section 130c Paragraph 1 of the Fifth Social Security Code - TEIZEILD active ingredient Teplizumab ATC A10XX01

Germany, June 18 -- Germany based Sanofi-Aventis Deutschland GmbH has secured contract from DAK-Gesundheit for Pharmaceutical products drug framework discount agreement in accordance with Section 130a Paragraph 8 and Section 130c Paragraph 1 of the Fifth Social Security Code - TEIZEILD active ingredient Teplizumab ATC A10XX01 . The value of the contract is not disclosed .

Published by HT Digital Content Services with permission from Pivotal Sources....